The prognostic value of T1 mapping and late gadolinium enhancement cardiovascular magnetic resonance imaging in patients with light chain amyloidosis

被引:73
作者
Lin, Lu [1 ,2 ]
Li, Xiao [1 ,2 ]
Feng, Jun [2 ,3 ]
Shen, Kai-ni [2 ,3 ]
Tian, Zhuang [2 ,4 ]
Sun, Jian [2 ,5 ]
Mao, Yue-ying [2 ,3 ]
Cao, Jian [1 ,2 ]
Jin, Zheng-yu [1 ,2 ]
Li, Jian [2 ,3 ]
Selvanayagam, Joseph B. [6 ]
Wang, Yi-ning [1 ,2 ]
机构
[1] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Radiol, 1 Shuaifuyuan, Beijing 100730, Peoples R China
[2] Peking Union Med Coll, 1 Shuaifuyuan, Beijing 100730, Peoples R China
[3] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Hematol, 1 Shuaifuyuan, Beijing 100730, Peoples R China
[4] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Cardiol, 1 Shuaifuyuan, Beijing 100730, Peoples R China
[5] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Pathol, 1 Shuaifuyuan, Beijing 100730, Peoples R China
[6] Flinders Univ S Australia, Flinders Med Ctr, Dept Cardiovasc Med, Bedford Pk, Adelaide, SA 5042, Australia
基金
中国国家自然科学基金;
关键词
Light chain amyloidosis; Cardiovascular magnetic resonance imaging; T1; mapping; Late gadolinium enhancement; CARDIAC AMYLOIDOSIS; AL AMYLOIDOSIS; CLINICAL-APPLICATIONS; SYSTEMIC AMYLOIDOSIS; STAGING SYSTEM; BIOMARKERS; HEART; DIAGNOSIS; SURVIVAL; COHORT;
D O I
10.1186/s12968-017-0419-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Cardiac impairment is associated with high morbidity and mortality in immunoglobulin light chain (AL) type amyloidosis, for which early identification and risk stratification is vital. For myocardial tissue characterization, late gadolinium enhancement (LGE) is a classic and most commonly performed cardiovascular magnetic resonance (CMR) parameter. T1 mapping with native T1 and extracellular volume (ECV) are recently developed quantitative parameters. We aimed to investigate the prognostic value of native T1, ECV and LGE in patients with AL amyloidosis. Methods: Eighty-two patients (55.5 +/- 8.5 years; 52 M) and 20 healthy subjects (53.2 +/- 11.7 years; 10 M) were prospectively recruited. All subjects underwent CMR with LGE imaging and T1 mapping using a Modified Look-Locker Inversion-recovery (MOLLI) sequence on a 3 T scanner. Native T1 and ECV were measured semi-automatically using a dedicated CMR software. The left ventricular (LV) LGE pattern was classified as none, patchy, and global groups. Global LGE was considered when there was diffuse, transmural LGE in more than half of the short axis images. Follow-up was performed for all-cause mortality using Cox proportional hazards regression analysis and Kaplan-Meier survival curves. Results: The patients demonstrated an increase in native T1 (1438 +/- 120 ms vs. 1283 +/- 46 ms, P = 0.001) and ECV (43.9 +/- 10. 9% vs. 27.0 +/- 1.7%, P = 0.001) compared to healthy controls. Native T1, ECV and LGE showed significant correlation with Mayo Stage, and ECV and LGE showed significant correlation with echocardiographic E/E' and LV ejection fraction. During the follow-up for a median time of 8 months, 21 deaths occurred. ECV >= 44.0% (hazard ratio [HR] 7.249, 95% confidence interval (CI) 1.751-13.179, P = 0.002) and global LGE (HR 4.804, 95% CI 1.971-12.926, P = 0.001) were independently prognostic for mortality over other clinical and imaging parameters. In subgroups with the same LGE pattern, ECV >= 44.0% remained prognostic (log rank P = 0.029). Median native T1 (1456 ms) was not prognostic for mortality (Tarone-Ware, P = 0.069). Conclusions: During a short-term follow-up, both ECV and LGE are independently prognostic for mortality in AL amyloidosis. In patients with a similar LGE pattern, ECV remained prognostic. Native T1 was not found to be a prognostic factor.
引用
收藏
页数:11
相关论文
共 28 条
  • [1] T1 mapping and survival in systemic light-chain amyloidosis
    Banypersad, Sanjay M.
    Fontana, Marianna
    Maestrini, Viviana
    Sado, Daniel M.
    Captur, Gabriella
    Petrie, Aviva
    Piechnik, Stefan K.
    Whelan, Carol J.
    Herrey, Anna S.
    Gillmore, Julian D.
    Lachmann, Helen J.
    Wechalekar, Ashutosh D.
    Hawkins, Philip N.
    Moon, James C.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 (04) : 244 - 251
  • [2] Updates in Cardiac Amyloidosis: A Review
    Banypersad, Sanjay M.
    Moon, James C.
    Whelan, Carol
    Hawkins, Philip N.
    Wechalekar, Ashutosh D.
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2012, 1 (02):
  • [3] Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging
    Barison, A.
    Aquaro, G. D.
    Pugliese, N. R.
    Cappelli, F.
    Chiappino, S.
    Vergaro, G.
    Mirizzi, G.
    Todiere, G.
    Passino, C.
    Masci, P. G.
    Perfetto, F.
    Emdin, M.
    [J]. JOURNAL OF INTERNAL MEDICINE, 2015, 277 (05) : 605 - 614
  • [4] Independent Predictors of Survival in Primary Systemic (AL) Amyloidosis, Including Cardiac Biomarkers and Left Ventricular Strain Imaging: An Observational Cohort Study
    Bellavia, Diego
    Pellikka, Patricia A.
    Al-Zahrani, Ghormallah B.
    Abraham, Theodore P.
    Dispenzieri, Angela
    Miyazaki, Chinami
    Lacy, Martha
    Scott, Christopher G.
    Oh, Jae K.
    Miller, Fletcher A., Jr.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY, 2010, 23 (06) : 643 - 652
  • [5] LGE Provides Incremental Prognostic Information Over Serum Biomarkers in AL Cardiac Amyloidosis
    Boynton, Samuel J.
    Geske, Jeffrey B.
    Dispenzieri, Angela
    Syed, Imran S.
    Hanson, Theodore J.
    Grogan, Martha
    Araoz, Philip A.
    [J]. JACC-CARDIOVASCULAR IMAGING, 2016, 9 (06) : 680 - 686
  • [6] Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis
    Comenzo, R. L.
    Reece, D.
    Palladini, G.
    Seldin, D.
    Sanchorawala, V.
    Landau, H.
    Falk, R.
    Wells, K.
    Solomon, A.
    Wechalekar, A.
    Zonder, J.
    Dispenzieri, A.
    Gertz, M.
    Streicher, H.
    Skinner, M.
    Kyle, R. A.
    Merlini, G.
    [J]. LEUKEMIA, 2012, 26 (11) : 2317 - 2325
  • [7] Dabir D, 2014, J CARDIOVASC MAGN R, P1669
  • [8] Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis
    Dispenzieri, A
    Gertz, MA
    Kyle, RA
    Lacy, MQ
    Burritt, MF
    Therneau, TM
    Greipp, PR
    Witzig, TE
    Lust, JA
    Rajkumar, SV
    Fonseca, R
    Zeldenrust, SR
    McGregor, CGA
    Jaffe, AS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (18) : 3751 - 3757
  • [9] CMR-Based Differentiation of AL and ATTR Cardiac Amyloidosis
    Dungu, Jason N.
    Valencia, Oswaldo
    Pinney, Jennifer H.
    Gibbs, Simon D. J.
    Rowczenio, Dorota
    Gilbertson, Janet A.
    Lachmann, Helen J.
    Wechalekar, Ashutosh
    Gillmore, Julian D.
    Whelan, Carol J.
    Hawkins, Philip N.
    Anderson, Lisa J.
    [J]. JACC-CARDIOVASCULAR IMAGING, 2014, 7 (02) : 133 - 142
  • [10] Medical progress - The systemic amyloidoses
    Falk, RH
    Comenzo, RL
    Skinner, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (13) : 898 - 909